Werstiuk E S, Coote M, Griffith L, Shannon H, Steiner M
Department of Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Br J Psychiatry. 1996 Dec;169(6):758-65. doi: 10.1192/bjp.169.6.758.
The mechanism of the antidepressant action of electroconvulsive therapy (ECT) remains unknown. Based on previous work with antidepressant drugs and their effects on the noradrenergic system, we undertook this study to further determine the effects of ECT on selected indices of peripheral adrenoceptor function in depressed patients.
Binding parameters (Bmax and Kd) of platelet alpha 2- and leukocyte beta 2-adrenoceptors, plasma noradrenaline (NA), 3-methoxy-4-hydroxy-phenylglycol (MHPG) and cortisol levels were determined in 18 patients, prior to treatment and 14 days after the last of a series of ECTs, and compared with samples obtained from 18 matched control subjects.
Platelet alpha 2-adrenoceptor sites were significantly elevated in untreated patients compared with controls (P < 0.03), but leukocyte beta 2-adrenoceptor numbers did not differ. Treatment with ECT led to a significant reduction in platelet alpha 2-adrenoceptor numbers, whereas leukocyte beta 2-adrenoceptor densities increased. Pre-ECT plasma NA, MHPG, and cortisol levels were elevated in patients, compared with controls, and decreased following ECT, but these differences were not statistically significant. Post-ECT plasma NA and beta 2-adrenoceptor numbers were significantly, negatively correlated (P < 0.05).
These results suggest that platelet alpha 2-adrenoceptors are supersensitive in depressed patients and treatment with ECT results in down-regulation of these receptors, which may be interpreted as a primary therapeutic, "normalising' effect. The post-ECT changes in leukocyte beta 2-adrenoceptors are probably only secondary to the lower circulating plasma NA levels.
电休克疗法(ECT)的抗抑郁作用机制尚不清楚。基于先前关于抗抑郁药物及其对去甲肾上腺素能系统影响的研究,我们开展了这项研究,以进一步确定ECT对抑郁症患者外周肾上腺素能受体功能选定指标的影响。
测定了18例患者治疗前及一系列ECT最后一次治疗后14天血小板α2 - 肾上腺素能受体和白细胞β2 - 肾上腺素能受体的结合参数(Bmax和Kd)、血浆去甲肾上腺素(NA)、3 - 甲氧基 - 4 - 羟基苯乙二醇(MHPG)和皮质醇水平,并与18例匹配对照受试者的样本进行比较。
与对照组相比,未治疗患者的血小板α2 - 肾上腺素能受体位点显著升高(P < 0.03),但白细胞β2 - 肾上腺素能受体数量无差异。ECT治疗导致血小板α2 - 肾上腺素能受体数量显著减少,而白细胞β2 - 肾上腺素能受体密度增加。与对照组相比,患者ECT治疗前血浆NA、MHPG和皮质醇水平升高,ECT治疗后降低,但这些差异无统计学意义。ECT治疗后血浆NA与β2 - 肾上腺素能受体数量呈显著负相关(P < 0.05)。
这些结果表明,抑郁症患者血小板α2 - 肾上腺素能受体超敏,ECT治疗导致这些受体下调,这可能被解释为主要的治疗性“正常化”效应。ECT治疗后白细胞β2 - 肾上腺素能受体的变化可能仅是循环血浆NA水平降低的继发结果。